CATALYST PHARMACEUTICALS, INC. UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATIONCombined Financial Information • April 10th, 2023 • Catalyst Pharmaceuticals, Inc. • Pharmaceutical preparations
On December 17, 2022, Catalyst Pharmaceuticals, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Eisai Co., Ltd. (“Eisai”). Pursuant to the terms of the Purchase Agreement, on January 24, 2023, the Company acquired Eisai’s U.S. rights, title and interest in and to FYCOMPA®, an anti-epileptic medication (“Fycompa”), including certain related assets, intellectual property and product inventory (the “Transaction”) for $164.2 million in cash and liabilities.
